FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1561-1562 April 8, 2004 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The recent decision by the Food and Drug Administration (FDA) to postpone a decision on the proposal to switch levonorgestrel emergency contraception (sold under the brand name Plan B) to over-the-counter status suggests that the FDA's decision-making process is being influenced by political considerations. The data overwhelmingly demonstrate that emergency contraception is safe and effective when available without a prescription. Moreover, the evidence shows that the availability of emergency contraception does not result in a change in the usual behavior or contraceptive practices of the women who are its potential users. A treatment for any other condition, from hangnail to . . . [Full Text of this Article]

Related Letters:

The FDA, Politics, and Plan B
Burstein P. D., Stanford J. B., Hager W. D., Crockett S. A., Drazen J. M., Greene M. F., Wood A. J.J.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2413-2414, Jun 3, 2004. Correspondence

This article has been cited by other articles:

• Rest, K. M., Halpern, M. H. (2007). Politics and the Erosion of Federal Scientific Capacity: Restoring Scientific Integrity to Public Health Science. Am. J. Public Health 97: 1939-1944 [Abstract] [Full Text]  
• Marston, C., Meltzer, H., Majeed, A. (2005). Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys. BMJ 331: 271- [Abstract] [Full Text]  
• Gorelick, K. J., Marcus, D. M., Cohen, F. J., Jenny-Avital, E. R. (2005). What Ails the FDA?. NEJM 352: 2553-2555 [Full Text]  
• Raine, T. R., Harper, C. C., Rocca, C. H., Fischer, R., Padian, N., Klausner, J. D., Darney, P. D. (2005). Direct Access to Emergency Contraception Through Pharmacies and Effect on Unintended Pregnancy and STIs: A Randomized Controlled Trial. JAMA 293: 54-62 [Abstract] [Full Text]  
• Cantor, J., Baum, K. (2004). The Limits of Conscientious Objection -- May Pharmacists Refuse to Fill Prescriptions for Emergency Contraception?. NEJM 351: 2008-2012 [Full Text]  
• (2004). Emergency Contraception: Politics Trumps Science at the U.S. Food and Drug Administration. Obstet Gynecol 104: 220-221 [Full Text]  
• Fenichel, R. R (2004). Which drugs should be available over the counter?. BMJ 329: 182-183 [Full Text]  
• Steinbrook, R. (2004). Waiting for Plan B -- The FDA and Nonprescription Use of Emergency Contraception. NEJM 350: 2327-2329 [Full Text]  
• Burstein, P. D., Stanford, J. B., Hager, W. D., Crockett, S. A., Drazen, J. M., Greene, M. F., Wood, A. J.J. (2004). The FDA, Politics, and Plan B. NEJM 350: 2413-2414 [Full Text]